ALTEKS - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 196,565 | 428,971 | 303,438 | 332,148 | 405,005 | 273,547 | 323,685 | 397,360 |
| Profit before tax | 16,184 | 52,952 | 18,288 | 30,817 | 37,960 | 20,275 | 7,524 | 20,593 |
| Net profit | 13,669 | 44,933 | 15,545 | 26,087 | 32,266 | 17,404 | 4,971 | 16,282 |
| Equity | 105,575 | 150,508 | 166,052 | 192,140 | 224,445 | 241,849 | 246,820 | 263,102 |
| Liabilities | 74,039 | 123,178 | 76,692 | 50,422 | 25,681 | 43,927 | 52,819 | 86,717 |
| Non-current assets | 15,491 | 11,529 | 8,215 | 4,240 | 265 | 31,655 | 28,369 | 21,889 |
| Current assets | 164,123 | 262,157 | 234,529 | 238,322 | 249,861 | 254,121 | 271,270 | 327,930 |
| Total assets | 179,614 | 273,686 | 242,744 | 242,562 | 250,126 | 285,776 | 299,639 | 349,819 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 58,422 | 59,488 | 86,416 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +1.2% | +118.2% | -29.3% | +9.5% | +21.9% | -32.5% | +18.3% | +22.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 7.6% | 16.4% | 6.4% | 10.8% | 12.9% | 6.1% | 1.7% | 4.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 12.9% | 29.9% | 9.4% | 13.6% | 14.4% | 7.2% | 2.0% | 6.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 7.0% | 10.5% | 5.1% | 7.9% | 8.0% | 6.4% | 1.5% | 4.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 8.2% | 12.3% | 6.0% | 9.3% | 9.4% | 7.4% | 2.3% | 5.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.7 | 0.8 | 0.5 | 0.3 | 0.1 | 0.2 | 0.2 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 76,091 | 160,862 | 113,788 | 166,074 | 202,503 | 117,236 | 107,895 | 140,246 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
ALTEKS - Social security debts
The company had no debts to Sodra
ALTEKS - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-03-07 | 2025-03-07 | 12.3 |
| 2025-03-05 | 2025-03-06 | 12.08 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
ALTEKS, UAB (code 302423144) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €397.4K, up 22.8% year on year and 45.3% over two years, showing a clear upward sales trend across 2023–2025. Net profit in 2025 amounted to €16.3K, compared with €5.0K in 2024 and €17.4K in 2023, indicating a recovery after the weaker 2024 result. The 2025 profit margin was 4.1%, below 2023 but above 2024. At year-end 2025, total assets stood at €349.8K, supported by equity of €263.1K and liabilities of €86.7K. The balance sheet remained equity-heavy, with an equity ratio of 75.2% and debt-to-equity of 0.33. Asset turnover was 1.14x, while ROE was 6.2% and ROA 4.7%. The company also reported revenue per employee of €198.7K and profit per employee of €8.1K, pointing to solid operational productivity in 2025.